|
|
|
|
Friday, May 8, 2020
Trovagene (TROV)
New CEO, New Name, Still a Promising Cancer Drug
Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company’s clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.
Cosme Ordonez, MD, Ph.D., Senior Life Sciences Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Financial Results in line with expectations. Trovagene, Inc. yesterday released Q1/F2020 financial results. The Company reported a net loss of $(4.1) mm and total operating expenses of $4.2 mm compared to $(4.2) mm and $4.0 mm, respectively, in Q1/F2019. Net cash used in operations was $3.37 mm in Q1/F2020, compared to $3.36 mm in Q1/F2019. The Company finished the quarter with $9.3 mm in cash and cash equivalents. Overall, the results were in line with our expectations.
New name is Cardiff Oncology, Inc. Trovagene announced a name change to Cardiff Oncology, Inc. The Company’s Nasdaq ticker symbol will change to CRDF, which will become effective at the open of the market on…
Click to get the full report.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
